Cargando…
Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection
Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674935/ https://www.ncbi.nlm.nih.gov/pubmed/34911696 http://dx.doi.org/10.1183/16000617.0194-2021 |
_version_ | 1784615776289816576 |
---|---|
author | Mylvaganam, Ruben J. Bailey, Joseph I. Sznajder, Jacob I. Sala, Marc A. |
author_facet | Mylvaganam, Ruben J. Bailey, Joseph I. Sznajder, Jacob I. Sala, Marc A. |
author_sort | Mylvaganam, Ruben J. |
collection | PubMed |
description | Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and Middle East respiratory syndrome) suggest that pulmonary fibrosis will contribute to long-term respiratory morbidity, suggesting that PASC-pulmonary fibrosis should be thoroughly screened for through pulmonary function testing and cross-sectional imaging. As data accumulates on the unique pathobiologic mechanisms underlying critical COVID-19, a focus on corollaries to the subacute and chronic profibrotic phenotype must be sought as well. Key aspects of acute COVID-19 pathobiology that may account for increased rates of pulmonary fibrosis include monocyte/macrophage–T-cell circuits, profibrotic RNA transcriptomics, protracted elevated levels of inflammatory cytokines, and duration of illness and ventilation. Mechanistic understanding of PASC-pulmonary fibrosis will be central in determining therapeutic options and will ultimately play a role in transplant considerations. Well-designed cohort studies and prospective clinical registries are needed. Clinicians, researchers and healthcare systems must actively address this complication of PASC to minimise disability, maximise quality of life and confront a post-COVID-19 global health crisis. |
format | Online Article Text |
id | pubmed-8674935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-86749352021-12-17 Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection Mylvaganam, Ruben J. Bailey, Joseph I. Sznajder, Jacob I. Sala, Marc A. Eur Respir Rev COVID-19 Reviews Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and Middle East respiratory syndrome) suggest that pulmonary fibrosis will contribute to long-term respiratory morbidity, suggesting that PASC-pulmonary fibrosis should be thoroughly screened for through pulmonary function testing and cross-sectional imaging. As data accumulates on the unique pathobiologic mechanisms underlying critical COVID-19, a focus on corollaries to the subacute and chronic profibrotic phenotype must be sought as well. Key aspects of acute COVID-19 pathobiology that may account for increased rates of pulmonary fibrosis include monocyte/macrophage–T-cell circuits, profibrotic RNA transcriptomics, protracted elevated levels of inflammatory cytokines, and duration of illness and ventilation. Mechanistic understanding of PASC-pulmonary fibrosis will be central in determining therapeutic options and will ultimately play a role in transplant considerations. Well-designed cohort studies and prospective clinical registries are needed. Clinicians, researchers and healthcare systems must actively address this complication of PASC to minimise disability, maximise quality of life and confront a post-COVID-19 global health crisis. European Respiratory Society 2021-12-15 /pmc/articles/PMC8674935/ /pubmed/34911696 http://dx.doi.org/10.1183/16000617.0194-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | COVID-19 Reviews Mylvaganam, Ruben J. Bailey, Joseph I. Sznajder, Jacob I. Sala, Marc A. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection |
title | Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection |
title_full | Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection |
title_fullStr | Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection |
title_full_unstemmed | Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection |
title_short | Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection |
title_sort | recovering from a pandemic: pulmonary fibrosis after sars-cov-2 infection |
topic | COVID-19 Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674935/ https://www.ncbi.nlm.nih.gov/pubmed/34911696 http://dx.doi.org/10.1183/16000617.0194-2021 |
work_keys_str_mv | AT mylvaganamrubenj recoveringfromapandemicpulmonaryfibrosisaftersarscov2infection AT baileyjosephi recoveringfromapandemicpulmonaryfibrosisaftersarscov2infection AT sznajderjacobi recoveringfromapandemicpulmonaryfibrosisaftersarscov2infection AT salamarca recoveringfromapandemicpulmonaryfibrosisaftersarscov2infection |